An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study)

This article has no abstract
Epistemonikos ID: 3217d44c26acb58e11a6411feef6966920ea6666
First added on: May 28, 2025